New Drug Combination for Advanced Hormone-Receptor Positive Breast Cancer
Part of Cancer, Skin clinical trials.
This study tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) for women with advanced breast cancer that is hormone-receptor positive and HER2-negative, with a specific genetic mutation (PIK3CA). The goal is to see if this combination can shrink or control the cancer better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Female, age 18 or older, and either postmenopausal (age 60+, or younger with 12+ months without periods and confirmed hormone levels) or willing to take an LHRH agonist injection every month
- Diagnosed with advanced or metastatic breast cancer (spread beyond the breast) that cannot be cured with surgery or radiation alone
- Cancer is hormone-receptor positive (ER/PR positive) and HER2-negative, confirmed by recent biopsy
- Genetic test shows PIK3CA mutation in your cancer (blood or tumor tissue)
- Cancer got worse during or within 12 months after finishing hormone therapy (like aromatase inhibitors or tamoxifen)
- At least one measurable tumor visible on imaging (not just bone-only metastases)
- Good overall health and able to take pills by mouth and receive injections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) compared to a placebo plus two of the drugs (ribociclib and fulvestrant) for people with advanced hormone receptor-positive breast cancer who have not had prior treatment for advanced disease. The goal is to see if adding inavolisib improves outcomes.
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
This trial tests a new drug, inavolisib, combined with two standard treatments (fulvestrant and palbociclib) for people with advanced breast cancer and type 2 diabetes. It aims to find out if this combination is safe and effective.
This trial is testing a drug called Inavolisib (a type of targeted therapy) given before surgery for people with early-stage, hormone receptor-positive, HER2-negative breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding Inavolisib to standard endocrine therapy can shrink the tumor more effectively.
This study observes how inavolisib (a new cancer drug) works in patients with a specific type of advanced breast cancer in everyday clinical practice. Researchers will track your medical records, imaging, and lab results over time to understand how well the treatment works and its safety profile.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.